Unlocking lesion-level insights to make oncology trials smaller and faster


Tumor heterogeneity

60% of cancer patients develop a mixture of shrinking, stable, and growing tumors. Tumor heterogeneity poses a significant obstacle to personalized cancer medicine and impedes our understanding of long-term treatment outcomes.

Every tumor matters to cure cancer

Our Approach

AI-powered treatment efficacy assessment

Incorporating all lesions to confirm treatment outcomes sooner with smaller sample sizes

AI Automation

Extract all-lesion features beyond current response evaluation criteria

AI Prediction

Explore all-lesion biomarkers that predict treatment outcome